首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Application of Fragment‐Based Screening to the Design of Inhibitors of Escherichia coli DsbA
Authors:Dr Luke A Adams  Dr Pooja Sharma  Dr Biswaranjan Mohanty  Olga V Ilyichova  Dr Mark D Mulcair  Dr Martin L Williams  Ellen C Gleeson  Dr Makrina Totsika  Dr Bradley C Doak  Dr Sofia Caria  Dr Kieran Rimmer  Dr James Horne  Dr Stephen R Shouldice  Mansha Vazirani  Dr Stephen J Headey  Brent R Plumb  Prof Jennifer L Martin  Dr Begoña Heras  Dr Jamie S Simpson  Dr Martin J Scanlon
Institution:1. Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052 (Australia) http://www.pharm.monash.edu.au;2. School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD 4072 (Australia);3. Present address: Institute of Health and Biomedical, Innovation, Queensland University of Technology, Kelvin Grove, QLD 4059 (Australia);4. Institute for Molecular Bioscience, University of Queensland, St. Lucia, QLD 4072 (Australia);5. Present address: La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086 (Australia)
Abstract:The thiol‐disulfide oxidoreductase enzyme DsbA catalyzes the formation of disulfide bonds in the periplasm of Gram‐negative bacteria. DsbA substrates include proteins involved in bacterial virulence. In the absence of DsbA, many of these proteins do not fold correctly, which renders the bacteria avirulent. Thus DsbA is a critical mediator of virulence and inhibitors may act as antivirulence agents. Biophysical screening has been employed to identify fragments that bind to DsbA from Escherichia coli. Elaboration of one of these fragments produced compounds that inhibit DsbA activity in vitro. In cell‐based assays, the compounds inhibit bacterial motility, but have no effect on growth in liquid culture, which is consistent with selective inhibition of DsbA. Crystal structures of inhibitors bound to DsbA indicate that they bind adjacent to the active site. Together, the data suggest that DsbA may be amenable to the development of novel antibacterial compounds that act by inhibiting bacterial virulence.
Keywords:bacterial virulence  drug design  EcDsbA  fragment‐based drug discovery  medicinal chemistry
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号